Nektar Therapeutics (NKTR)
NASDAQ: NKTR · Real-Time Price · USD
0.6400
+0.0332 (5.47%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Nektar Therapeutics Stock Forecast
NKTR's stock price has decreased by -57.05% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Nektar Therapeutics stock have an average target of 4.92, with a low estimate of 2.00 and a high estimate of 7.00. The average target predicts an increase of 668.75% from the current stock price of 0.64.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Nektar Therapeutics stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 3 | 3 | 3 | 4 |
| Buy | 2 | 2 | 1 | 1 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 0 | 0 |
| Sell | 1 | 1 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jefferies | Jefferies | Hold → Strong Buy Upgrades $1 → $2 | Hold → Strong Buy | Upgrades | $1 → $2 | +212.50% | Apr 11, 2025 |
| Oppenheimer | Oppenheimer | Hold → Buy Upgrades $6 | Hold → Buy | Upgrades | $6 | +837.50% | Mar 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $6.5 | Strong Buy | Reiterates | $6.5 | +915.63% | Mar 13, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $6.5 | Strong Buy | Reiterates | $6.5 | +915.63% | Feb 25, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $6.5 | Strong Buy | Reiterates | $6.5 | +915.63% | Jan 13, 2025 |
Financial Forecast
Revenue This Year
74.43M
from 98.43M
Decreased by -24.38%
Revenue Next Year
70.08M
from 74.43M
Decreased by -5.84%
EPS This Year
-0.67
from -0.58
EPS Next Year
-0.74
from -0.67
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 136.6M | 139.4M | 138.9M | ||
| Avg | 74.4M | 70.1M | 81.4M | ||
| Low | 44.7M | 24.4M | 47.0M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 38.8% | 87.3% | 98.3% | ||
| Avg | -24.4% | -5.8% | 16.1% | ||
| Low | -54.5% | -67.3% | -32.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.36 | -0.39 | -0.23 | ||
| Avg | -0.67 | -0.74 | -0.88 | ||
| Low | -0.77 | -1.21 | -1.78 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.